



Acura Pharmaceuticals to Present at the Needham Healthcare Conference on April 3, 2012

Palatine, IL - (March 21, 2012) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating [abuse deterrent drugs](#), announced today that the company will present at the 11th Annual Needham Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, April 3. Bob Jones, Acura Pharmaceutical's Chief Executive Officer, will provide a company overview at 3:20 PM Eastern Time.

During the presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. A live webcast of the presentation will be available through the Investor page of Acura's website: www.acurapharm.com. An archived version of the presentation will be available for 30 days after the event.

Utilizing its proprietary AVERSION® and IMPEDE™ technologies, Acura develops products intended to address [medication abuse and misuse](#). AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nose. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address [medication abuse and misuse](#), utilizing its proprietary AVERSION and IMPEDE technologies. In June 2011, the U.S. Food and Drug Administration approved the first product incorporating the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products and its IMPEDE technology for pseudoephedrine hydrochloride products.

Contact:

Stephanie Marks for Acura Investor Relations
smarks@lazarpartners.com
212-843-0211

Rachel Kessler for Acura Media Relations
rkessler@lazarpartners.com
917-660-0608